Directors Shareholdings

RNS Number : 5361Y

Deltex Medical Group PLC

23 December 2010

 



 

 

Deltex Medical Group plc

Directors' Shareholdings/Issue of equity

23 December 2010 Deltex Medical Group plc ("Deltex Medical" or the "Company"), the global leader in oesophageal Doppler monitoring ("ODM"), announces that it has today issued a total of 124,602 new ordinary shares of 1p each in the Company ("New Ordinary Shares") at a price of 19.50 pence per share.

The four non-executive directors named below have elected to take New Ordinary Shares in lieu of a cash payment as remuneration for their services to the Company for the period 1 October 2010 to 31 December 2010.

Paul Mitchell has elected to take New Ordinary Shares in lieu of £2,704 of salary in respect of the period 1 October 2010 to 31 December 2010.

Accordingly, application has been made for these New Ordinary Shares to be admitted to trading on AIM. The shares rank pari passu with the existing issued shares of the Company and dealings are expected to commence on 31 December 2010.  Following the issue of these new shares the Company has a total of 132,025,866 ordinary shares of 1p each in issue.

Following this issue, the directors' beneficial interests are as follows:

Name of Director	Number of New Ordinary Shares issued in lieu of fees/salary	Holding of shares following issue of New Ordinary Shares	% of enlarged issued share capital
Nigel Keen	42,735	5,633,804	4.27
Dr Edwin Snape (1)	30,769	4,392,724	3.33
Sir Duncan Nichol	18,462	602,107	0.46
Julian Cazalet	24,455	3,455,388	2.62
Paul Mitchell	8,181	130,501	0.10

(1)     Includes shares held as a principal of Nexus Medical Partners II, L.P.

For further information, please contact:-

Deltex Medical Group plc                                                                                01243 774 837
Nigel Keen, Chairman                                        
Ewan Phillips, Chief Executive                           
Paul Mitchell, Finance Director               

Nominated Adviser and Broker                                                                        0207 614 5917

Arden Partners plc 

Christopher Hardie

 

END

 

 

MSCUOSURRUAUUAA